PROCEPT BioRobotics Corporation (PRCT) Downgraded to Market Perform by William Blair

Market Context

PROCEPT BioRobotics Corporation operates in the Healthcare sector. The stock currently trades at $18.28 with a market capitalization of $2.0B. The stock has declined 62.1% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow William Blair's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for PROCEPT BioRobotics Corporation

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 05, 2026	William Blair	Market Perform	N/A
Jul 06, 2026	Truist Securities	Hold	N/A
Jun 24, 2026	Evercore ISI Group	Outperform	N/A
Jun 11, 2026	Leerink Partners	Market Perform	N/A
Apr 30, 2026	Piper Sandler	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View PRCT Stock Page